GlaxoSmithKline plc Sponsored ADR(GSK.US) obtains approval for new indications for its long-acting monoclonal antibody drug in China and launches on the market.

On April 3rd, the NMPA website showed that GlaxoSmithKline plc Sponsored ADR(GSK.US) received approval for a new indication for the drug "Depemokimab" for the treatment of chronic rhinosinusitis with nasal polyps. Depemokimab is a new generation anti-interleukin-5 (IL-5) monoclonal antibody developed by GSK, with a long half-life, high binding affinity, and high efficacy. It is the world's first semi-annual ultra-long-acting IL-5 biological agent. In December 2025, Depemokimab was globally launched in the US for the treatment of eosinophilic asthma. In March 2026, Depemokimab made its debut in the Chinese market for the first time. This is the second indication approved for Depemokimab in China. GSK has a strong and industry-leading respiratory product pipeline. The approved Depemokimab this time is an iteration product of the monthly IL-5 monoclonal antibody "Mepolizumab" (Nucala), which is expected to take over as the successor to this blockbuster drug with annual revenue of $2.651 billion in 2025, becoming the next market leader.